digital health

Our Vision of Autoimmune Care

Autoimmune Patient Journey The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Unlike cancer, diabetes, and heart disease, there are no population screening nor public health education programs for AIIDs. This blocks the path to early diagnosis and preventative autoimmune care.  As early symptoms fluctuate

Read More »

Autoimmune Incidence & Prevalence

Data Issues in Autoimmune Data for autoimmune diseases are substantially lacking and inconsistent. The US gathers no statistics on autoimmune diseases as a group, nor even national data on marquee diseases. Therefore, total autoimmune incidence & prevalence figures are, at best, estimates. Unlike cancer, there is no national strategic research

Read More »

The Chronic Disease Epidemic: Visible & Invisible

The Visible Chronic Disease Epidemic Click the arrows next to the slide to view the sources. The chronic disease population has grown substantially in recent years since modern medicine has extended the human lifespan. Depending on sources, 40-60% of Americans (128-140M people) have one or more chronic health conditions. Moreover,

Read More »

Long and Frustrating Autoimmune Patient Journeys (Part 1)

Slow & Uncoordinated Path to Diagnosis & Treatment Today, autoimmune patient journeys are typically long, convoluted, and frustrating; from first awareness of symptoms to scheduling medical visits, diagnosis, treatment, and long-term care. Since many autoimmune & inflammatory diseases (AIIDs) emerge in youth or middle age and last a lifetime, the

Read More »

Specialty Pharmaceuticals: The Highest Autoimmune Cost

Invisible Epidemic of Autoimmune Disease As we continue to illuminate the hidden costs of the long-ignored epidemic of autoimmune disease (AIID), we must shine a light on the highest autoimmune cost: Specialty pharmaceuticals. Current data largely underestimate total AIID costs, and accurate numbers are few and far between. Through our

Read More »

Stanford MedX Autoimmune 2014-17 Presentations by DrBonnie360

We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an

Read More »

Our pre-Covid vision of autoimmune business opportunities

Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within

Read More »

Digital GI Health: Sam Holliday, CEO, Oshi Health – Part 2
Coordinating primary with specialty care, redesigning virtual GI care around patients

A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi

Read More »